Track topics on Twitter Track topics that are important to you
The Company's technologies are based on discoveries arising from research conducted at the University of Calgary. Dr. Coffey, VP Product Development for the Company was instrumental in these discoveries, and continues to be instrumental in the product development process.
The Company was formed in 1998, to explore the natural oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated Ras pathway.
The product being developed by the Company may represent a novel treatment for certain tumor types and some cellular proliferative disorders. The Company’s product is a virus that is able to replicate specifically in, and hence kill, certain tumor cells both in tissue culture as well as in a number of animal models.
The Company’s product for human use, REOLYSIN®, is the reovirus. This virus has been demonstrated to replicate specifically in tumor cells bearing an activated Ras pathway. Activating mutations of Ras and upstream elements of Ras may play a role in greater than two thirds of all potential tumors.
210, 1167 Kensington Crescent
AB T2N 1X7
Phone: (403) 670-7377
Fax: (403) 283-0858
Oncolytics Biotech traded up 0.75% during trading on Friday, hitting $0.41. The company's stock had a trading volume of 33,326 shares.
Headlines about Oncolytics Biotech have been trending somewhat positive this week, according to Accern Sentiment. The research group rates the sentiment of press coverage by reviewing more than twenty...
Windtree Therapeutics and Oncolytics Biotech are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, an...
Dr. Brad Thompson, CEO of Oncolytics Biotech talks through the solid science that underpins his company. Whilst describing the company’s story to date he discusses overcoming the regulatory hurdles ...
Adlai Nortye, a Hangzhou company, entered a $86.6 million iin-licensing agreement to develop and market a novel immuno-oncolytic virus in Greater China that was discovered by Canada's Oncolytics Biote...
Life Sciences Jobs ...
Oncolytic viruses (OVs) are emerging as powerful anti-cancer agents and are currently being tested for their safety and efficacy in patients. Reovirus (Reolysin), a naturally occurring non-pathogenic,...
Oncolytics Biotech Inc. was formed in 1998 to develop its proprietary product, REOLYSIN®, as a potential therapeutic for a wide variety of human cancers. Oncolytics has completed five clinical trials...
The Company's technologies are based on discoveries arising from research conducted at the University of Calgary. Dr. Coffey, VP Product Development for the Company was instrumental in these discoveri...
We have published hundreds of Oncolytics news stories on BioPortfolio along with dozens of Oncolytics Clinical Trials and PubMed Articles about Oncolytics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Oncolytics Companies in our database. You can also find out about relevant Oncolytics Drugs and Medications on this site too.